Liver disease | Mitochondrial dysfunction | Source | Delivery route | Potential mechanism | Ref |
---|---|---|---|---|---|
NAFLD | Abnormal lipid metabolism and calcium homeostasis | Human bone marrow | Intrasplenic injection | Mitochondrial transfer via TNT | [8] |
Rat bone marrow | Tail vein | Restoring sarcoplasmic/ER Ca2+ ATPase activity to alleviate of ER stress | [46] | ||
CCl4-induced liver injury | Oxidant/antioxidant imbalance | Human bone marrow | Tail vein | Increasing SOD activity and inhibiting ROS production | [47] |
Human umbilical cord | Tail vein | Presented more distinct antioxidant by EVs | [48] | ||
APAP and H2O2-induced liver injury | Oxidant/antioxidant imbalance | Rat bone marrow | Intrahepatic injection | Fractionated MSC exosomes reduce ROS activity more efficiently | [49] |
Oxidant/antioxidant imbalance | Mouse adipose tissue | Tail vein | Increasing hepatic GSH level and alleviate ROS accumulation | [10] | |
D-galactose induced liver injury | Oxidant/antioxidant imbalance | Human umbilical cord | Tail vein | Reducing oxidative stress via activation of Nrf2/HO-1 pathway | [50] |
Hepatic I/R injury | Oxidant/antioxidant imbalance | Human umbilical cord | Tail vein | Suppressing oxidative stress by MnSOD encapsulated in EVs | [21] |
Impaired mitophagy | Human umbilical cord | Peripheral vein | Reducing Parkin and PINK1 expression and inactivating AMPKα pathway | [22] | |
Post-hepatectomy liver failure | Impaired mitochondrial dynamics | Mouse bone marrow | Portal vein | Downregulating p-Drp1 and FIS1 expression and upregulating MFN2 | [7] |
Abnormal lipid metabolism | Reducing mitochondrial damage and secreting IL-10 | ||||
Liver cirrhosis | Abnormal lipid metabolism | Human placenta | Tail vein | Attenuating ER stress via activating the EGFR-PI3K-CaM Pathway by PRL-1 | [51] |